MENU

MTNB Stock Tickeron detected bullish Stock Pattern: Triangle Symmetrical Bottom on February 19, 2025

A.I.dvisor
at Tickeron.com
Loading...
Triangle Symmetrical Bottom
MTNB - Matinas Biopharma Holdings Inc
Tickeron
Emerged: 02/19/25
Breakout: $0.6576
Price: $0.5708
Target price: $0.759
A.I.dvisor detected a bullish Triangle Symmetrical Bottom pattern for MTNB stock. This pattern was detected on February 19, 2025 . The odds of reaching the target price are 7. The Symmetrical Triangle Bottom pattern forms when the price of a security fails to retest a high or a low and ultimately forms two narrowing trend lines. As the support and resistance levels consolidate, they form a triangle. Consider buying a security or call option at the breakout price level. When trading, wait for the confirmation move, which is when the price rises above the breakout level.

Momentum Indicator for MTNB turns positive, indicating new upward trend

MTNB saw its Momentum Indicator move above the 0 level on February 13, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 74 cases where MTNB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

MTNB moved above its 50-day moving average on February 21, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MTNB crossed bullishly above the 50-day moving average on February 21, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where MTNB advanced for three days, in of 213 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MTNB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MTNB broke above its upper Bollinger Band on February 21, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for MTNB entered a downward trend on February 13, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.206) is normal, around the industry mean (12.481). P/E Ratio (0.000) is within average values for comparable stocks, (84.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.603). MTNB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (34.843) is also within normal values, averaging (251.221).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MTNB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MTNB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
MTNB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1545 Route 206 South
Phone
+1 908 484-8805
Employees
32
Web
https://www.matinasbiopharma.com